
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.
Title: Medical Writer, Regulatory (Contract)
Reports to: Sr. Director, Medical Writing
Location: Remote (West coast hours preferred)
Duration: Through December 2026 with potential extension based on business needs
Hours: Approximately 20 hours per week, with flexibility needed based on project demands
Hourly rate: $170-$190/hr
Kyverna is seeking an experienced Contract Medical Writer to provide regulatory medical writing support for development programs. This individual will serve as an independent contributor responsible for developing high-quality regulatory documents supporting FDA interactions and clinical development activities.
The ideal candidate brings extensive medical writing experience in Autoimmune diseases (Stiff Person Syndrome, Myasthenia Gravis, Progressive Multiple Sclerosis) and has a proven ability to independently author complex regulatory documents with minimal oversight. This role will partner closely with Clinical Development, Regulatory Affairs, Clinical Operations, and other cross-functional stakeholders to support critical regulatory milestones.

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.